Agile Therapeutics Strengthens Executive Leadership Team with New Chief Commercial Officer
07 7월 2016 - 5:15AM
Agile Therapeutics, Inc., (NASDAQ:AGRX), a women's health specialty
pharmaceutical company focused on the development and
commercialization of new prescription contraceptive products, today
announced that it had strengthened its executive leadership team
with the appointment of Renee Selman as its new Chief Commercial
Officer. Ms. Selman is a former senior executive at Johnson
& Johnson (“J&J”) who led the commercial launch of ORTHO
EVRA®, one of the most successful contraceptive launches in the U.S
and the first ever contraceptive patch. Ms. Selman succeeds
Katie MacFarlane, who has chosen to return to her previous role as
an advisor to the Company as managing partner of SmartPharma LLC,
in order to grow that business.
“We are pleased to welcome Renee to our senior
management team at an exciting time for Agile,” said Al Altomari,
President and Chief Executive Officer of Agile. “We believe
her extensive experience in the commercialization of important new
drugs in women’s health will be valuable as we continue to develop
and seek approval for our lead product candidate, Twirla® and seek
to expand our pipeline. Renee’s experience with managing the
launch of the first-ever contraceptive patch, ORTHO EVRA, makes her
well suited to lead the commercial preparations for Twirla.”
Most recently, Ms. Selman served as President of
Adheris Health, a business unit of inVentiv Health, from 2010 until
2015. Adheris Health is one of the nation’s largest providers
of targeted patient acquisition and adherence programs. Their
evidence-based behavioral interventions help patients stay on their
prescribed therapy. Ms. Selman spent 20 years at J&J
where she held senior executive roles including Worldwide
President, Ethicon Women’s Health and Urology from 2005 to 2010,
and Vice President U.S. Sales and Marketing Wound Management from
2003 to 2005. While at J&J, she held roles of increasing
responsibility at Ortho McNeil Pharmaceutical, including Group
Director ORTHO EVRA from 1999 to 2003, where she led a cross
functional team that launched the first ever contraceptive patch.
Ms. Selman serves on the boards of the Hunterdon County Medical
Center, the Drug Information Association, and the Purdue University
Krannert School of Management Alumni Board. She is a graduate
of Purdue University with a B.S.I.M (Bachelor Science Industrial
Management) in Business and a minor in Chemistry.
Ms. MacFarlane will continue to work with the
Company in her role as managing partner of SmartPharma. The Company
acknowledges the valuable contributions Ms. MacFarlane has made to
the company over the past several years. “We thank Katie for her
many contributions to Agile and wish her the best as she pursues
her goal of growing SmartPharma,” said Mr. Altomari.
About Agile Agile Therapeutics
is a women's health specialty pharmaceutical company focused on the
development and commercialization of new prescription contraceptive
products. Our product candidates are designed to provide women with
contraceptive options that offer greater convenience and facilitate
compliance. Our lead product candidate, Twirla®, (ethinyl estradiol
and levonorgestrel transdermal system), also known as AG200-15, is
a once-weekly prescription contraceptive patch currently in Phase 3
clinical development. Twirla is based on our proprietary
transdermal patch technology, called Skinfusion®, which is designed
to provide advantages over currently available patches and is
intended to optimize patch adherence and patient acceptability. For
more information, please visit the company website at
www.agiletherapeutics.com. The company may occasionally disseminate
material, nonpublic information on the company website.
Forward-Looking
StatementCertain information contained in this press
release includes "forward-looking statements" related to the
Company's, projected cash position, timeline for clinical trials
and potential market opportunity for its product candidates. We
may, in some cases use terms such as "predicts," "believes,"
"potential," "continue," "anticipates," "estimates," "expects,"
"plans," "intends," "may," "could," “might," "will," "should" or
other words that convey uncertainty of the future events or
outcomes to identify these forward-looking statements. Our
forward-looking statements are based on current expectations that
involve risks, potential changes in circumstances, assumptions and
uncertainties. Any or all of the forward-looking statements may
turn out to be wrong, or be affected by inaccurate assumptions we
might make or by known or unknown risks and uncertainties. For
example, our statements about our projected cash position could be
affected by market factors, the inherent risks in our business, our
ability to execute the Company’s operational and budget plans, and
unforeseen events in our clinical and manufacturing development
plans; our statements about the timing of completion of our
clinical trials and our ability to potentially commercialize our
product candidates, we identify serious side effects or other
safety issues, we do not have clinical supply of our product
candidate that is adequate in amount and quality and supplied in a
timely fashion, and the inherent risks of clinical development; our
statements about the potential commercial opportunity could be
affected by the potential that our product does not receive
regulatory approval, does not receive reimbursement by third party
payors, or a commercial market for the product does not develop
because of any of the risks inherent in the commercialization of
contraceptive products. For all these reasons, actual results and
developments could be materially different from those expressed in
or implied by our forward-looking statements. All forward looking
statements are subject to risks detailed in our filings with the
U.S. Securities and Exchange Commission, including the Company's
Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q.
You are cautioned not to place undue reliance on these
forward-looking statements, which are made only as of the date of
this press release. We undertake no obligation to publicly update
such forward-looking statements to reflect subsequent events or
circumstances.
Contact: Mary Coleman
609-683-1880 x6511
Head of Investor Relations and Public Relations
Agile Therapeutics (NASDAQ:AGRX)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Agile Therapeutics (NASDAQ:AGRX)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024